Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR5287)

Aquitaine Institute for Cognitive and Integrative Neuroscience

Université de Bordeaux

Zone nord Bat 2 2ème étage
146, rue Léo Saignat
33076 Bordeaux cedex


Supervisory authorities

CNRS Ecole Pratique des Hautes Etudes Université de Bordeaux

Our partners

Neurocampus Unitéde Formation de Biologie


GDR Robotique GDR Mémoire GDR Multi-électrodes


Home > Teams > PET Research (P. FERNANDEZ)


by Lamare Frederic - published on , updated on


  • Hindié E, Morgat C (2019), Early use of abiraterone and radium-223 in metastatic prostate cancer., Lancet Oncol. 2019 May;20(5):e229. doi: 10.1016/S1470-2045(19)30235-9
  • Morgat C, Chastel A, Molinie V, Schollhammer R, Macgrogan G, Vélasco V, Malavaud B, Fernandez P, Hindié E (2019), Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. Int J Mol Sci. 2019 Apr 7;20(7). pii: E1721. doi: 10.3390/ijms20071721.
  • Morgat C, Schollhammer R, Macgrogan G, Barthe N, Vélasco V, Vimont D, Cazeau AL, Fernandez P, Hindié E, Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples., PLoS One. 2019 Jan 15;14(1):e0210905
  • S. Vergnet, F. Hives, A. Foubert-Samier, P. Payoux, P. Fernandez, M. Meyer, J. Dupouy, C. Brefel-Courbon, F. Ory-Magne, O. Rascol, F. Tison, A. Pavy-Le Traon, W.G Meissner. (2019) : Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism & Related Disorders. S1353-8020(19)30037-9
  • E. Follenfant, N. Balamoutoff, S. Lawson-Ayayi, H. Dutronc, M. Dupon, J-M Vital, P. Delobel, H. Durox, H. de Clermont-Gallerande, P. Fernandez, F-A Dauchy (2019) : Added value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of post-operative instrumented spine infection. Joint Bone Spine. 2019 Jan 31. pii: S1297-319X(19)30008-9. doi: 10.1016/j.jbspin.2019.01.009


  • Laffon E, de Clermont H, Buj S, Marthan R., Should we assess repeatability of PET quantitative uptake measurements of each 18F-labelled tracer? Eur J Nucl Med Mol Imaging. 2018, 45(7):1272-1273.
  • Laffon E, de Clermont H, Marthan R, Paycha F., On the 18F-fluoride PET imaging quantification to predict 223Ra-dichloride treatment response. Eur J Nucl Med Mol Imaging. 2018, 45(2):318-320.
  • Cochin V, De Mones E, Digue L, Garcia-Ramirez M, Duoin C, Majoufre C, Fernandez P, Daste A., Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma. Targeted Oncology. 2018, 13(2) :247-252.
  • Tisseraud M, Schulz J, Vimont D, Berlande M, Fernandez P, Hermange P, Fouquet E., Highly hindered 2-(aryl-di-tert-butylsilyl)-N-methyl-imidazoles: a new tool for the aqueous 19F- and 18F-fluorination of biomolecule-based structures., Chem Commun (Camb). 2018 May 15;54(40):5098-5101
  • Mesguich C, Bouabdallah K, Milpied N, Hindié E.Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma., J Clin Oncol. 2018 May 23
  • Hindié E, Récher C, Zerdoud S, Leenhardt L, Avram AM., Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning., J Clin Oncol. 2018 Jun 20;36(18):1881-1882
  • Hindié E, Taïeb D, Avram AM, Giovanella L., Radioactive iodine ablation in low-risk thyroid cancer. Lancet Diabetes Endocrinol. 2018; 6(9):686
  • Giovanella L, Avram AM, Clerc J, Hindié E, Taïeb D, Verburg FA. Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?, Eur J Nucl Med Mol Imaging. 2018;45(12):2155-2158
  • de Vaugelade C, Mesguich C, Nubret K, Camou F, Greib C, Dournes G, Debordeaux F, Hindie E, Barandon L, Tlili G., Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of 18F-FDG PET/CT scan and leucocyte-labeled scintigraphy., J Nucl Cardiol. 2018 Jun 12. doi: 10.1007/s12350-018-1323-7
  • Imperiale A, Taïeb D, Hindié E.18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism., Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):654-65
  • Hindie E, Morgat C, Zanotti-Fregonara P, Haissaguerre M, Bordenave L, Tabarin A. Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. J Nucl Med. 2018 Mar;59(3):546-547.
  • Hindie E, Zanotti-Fregonara P, Morgat C. Somatostatin Antagonists for Radioligand Therapy of Non-Endocrine Tumors. J Nucl Med. 2018 Mar;59(3):544
  • Merlin T, Visvikis D, Fernandez P, Lamare F., Dynamic PET image reconstruction integrating temporal regularization associated with respiratory motion correction for applications in oncology. Phys Med Biol. 2018 Feb 13;63(4):045012
  • Debordeaux F., Schulz J., Chansel-Debordeaux L., Pinaquy J.B, Fernandez P., What About alpha(v)beta3 Integrins in Molecular Imaging in Oncology?, Nucl. Med. Biol. 2018, 62-63, 31-46. DOI : 10.1016/j.nucmedbio.2018.04.006


  • Clerc J, Verburg FA, Avram AM, Giovanella L, Hindie E, Taieb D. Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option. Eur J Nucl Med Mol Imaging. Jun 2017;44(6):918-925.
  • de Vaugelade C, de Clermont-Gallerande H, Meyer M, et al. FDG PET/CT in Pediatric Neurolymphomatosis. Clin Nucl Med. May 2017;42(5):e255-e257.
  • Delyon J, Chevret S, Jouary T, et al. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. J Invest Dermatol. Aug 24 2017.
  • Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. Jul 1 2017;102(7):2465-2472.
  • Guillot B, Dalac S, Denis MG, et al. French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol. Apr 2017;31(4):594-602.
  • Hindie E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017;7(5):1159-1163.
  • Hindie E, Mesguich C, Bouabdallah K, Milpied N. Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma". Eur J Nucl Med Mol Imaging. Oct 2017;44(11):1937-1939.
  • Hindie E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. Aug 2017;44(8):1254-1257.
  • Hindie E, Mesguich C, Zanotti-Fregonara P. On the Role of Interim Fluorine-18-Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma. J Clin Oncol. Aug 20 2017;35(24):2851-2852.
  • Houard C, Pinaquy JB, Mesguich C, et al. Role of (18)F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma. J Nucl Med. Sep 2017;58(9):1414-1420.
  • Mazere J, Lamare F, Allard M, Fernandez P, Mayo W. 123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies. J Nucl Med. Jan 2017;58(1):123-128.
  • Mesguich C, Cazeau AL, Bouabdallah K, Hindie E. Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee. Br J Haematol. Jan 20 2017.
  • Meyer M, Fernandez P, Zanotti-Fregonara P. 18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus. Clin Nucl Med. Jan 2017;42(1):42-43.
  • Meyer M, Le-Bras L, Fernandez P, Zanotti-Fregonara P. Standardized Input Function for 18F-FDG PET Studies in Mice: A Cautionary Study. PLoS One. 2017;12(1):e0168667.
  • Morgat C, MacGrogan G, Brouste V, et al. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. J Nucl Med. Sep 2017;58(9):1401-1407.
  • Rizzo G, Veronese M, Tonietto M, et al. Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities. J Cereb Blood Flow Metab. Jan 1 2017:271678X17742004.
  • Rugeri B, Audi H, Jewula P, et al. Designing Silylated l-Amino Acids using a Wittig Strategy: Synthesis of Peptide Derivatives and 18F-Labelling. European Journal of Organic Chenistry. 2017;2017(36):5399–5409.
  • Rugeri B, Audi H, Jewula P, Koudih R., Malacea-Kabbara R., Vimont D., Schulz J., Fernandez P., Jugé S., Modular Synthesis of Silylated L-Amino Acids and Peptides using Wittig Strategy and 18F-Labeling, Eur. J. Org. Chem 2017, 5399-5409. DOI : 10.1002/ejoc.201701170
  • Schollhammer R, De Clermont-Gallerande H, Fernandez P, Meyer M. Imaging of a Pelvic Textiloma Using (18)F-FDG PET/CT in a Patient With a History of Prostate Cancer: A Case Report and Review of the Literature. Clin Genitourin Cancer. Oct 2017;15(5):e859-e861.
  • Schollhammer R, Schwartz P, Jullie ML, et al. 18F-FDG PET/CT Imaging of Popliteal Vasculitis Associated With Polyarteritis Nodosa. Clin Nucl Med. Aug 2017;42(8):e385-e387.
  • Zanotti-Fregonara P, Hindie E. Performing nuclear medicine examinations in pregnant women. Phys Med. Nov 2017;43:159-164.
  • Zanotti-Fregonara P, Hindie E. Linear No-Threshold Hypothesis at the Hospital: When Radioprotection Becomes a Nosocomial Hazard. J Nucl Med. Aug 2017;58(8):1355.
  • Zanotti-Fregonara P, Hindie E. Re: 131I and 124I Accumulation in a Thymic Cyst. Clin Nucl Med. Jul 2017;42(7):576.
  • Zanotti-Fregonara P, Morgat C, Champion C, Hindie E. Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. Eur J Nucl Med Mol Imaging. Jun 2017;44(6):1095-1096.
  • Zanotti-Fregonara P, Stabin MG. New Fetal Radiation Doses for (18)F-FDG Based on Human Data. J Nucl Med. Nov 2017;58(11):1865-1866.
  • Zerdoud S, Giraudet AL, Leboulleux S, et al. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Ann Endocrinol (Paris). Jul 2017;78(3):162-175.


  • Amraoui S, Tlili G, Sohal M, Berte B, Hindie E, Ritter P, et al. Contribution of PET Imaging to the Diagnosis of Septic Embolism in Patients With Pacing Lead Endocarditis. JACC Cardiovasc Imaging. 2016 Mar;9(3):283-90.
  • Champion C, Quinto MA, Morgat C, Zanotti-Fregonara P, Hindie E. Comparison between Three Promising ss-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease. Theranostics. 2016;6(10):1611-8.
  • Dauchy FA, Dutertre A, Lawson-Ayayi S, de Clermont-Gallerande H, Fournier C, Zanotti-Fregonara P, et al. Interest of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of relapse in patients with spinal infection: a prospective study. Clin Microbiol Infect. 2016 May;22(5):438-43.
  • de Vaugelade C, Pinaquy JB, Fernandez P, Bordenave L, Hindie E, Zanotti-Fregonara P. Putative Physiopathological Explanation for the "Sock Sign" in Bone Scans. Clin Nucl Med. 2016 Sep;41(9):e420-1.
  • Deroose CM, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med. 2016 Dec;57(12):1949-56.
  • Fayad H, Lamare F, Merlin T, Visvikis D. Motion correction using anatomical information in PET/CT and PET/MR hybrid imaging. Q J Nucl Med Mol Imaging. 2016 Mar;60(1):12-24.
  • Groheux D, Biard L, Giacchetti S, Teixeira L, Hindie E, Cuvier C, et al. (1)(8)F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. J Nucl Med. 2016 Apr;57(4):536-43.
  • Groheux D, Cochet A, Humbert O, Alberini JL, Hindie E, Mankoff D. (1)(8)F-FDG PET/CT for Staging and Restaging of Breast Cancer. J Nucl Med. 2016 Feb;57 Suppl 1:17S-26S.
  • Groheux D, Hindie E. Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer? Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1571-3.
  • Groheux D, Mankoff D, Espie M, Hindie E. (1)(8)F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging. 2016 May;43(5):983-93.
  • Guillot B, Dalac S, Denis M, Dupuy A, Emile JF, De La Fouchardiere A, et al. [Guidelines for stage I to III melanoma]. Bull Cancer. 2016 Sep;103(9):743-52.
  • Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, et al. [Update to the recommendations for management of melanoma stages I to III]. Ann Dermatol Venereol. 2016 Oct;143(10):629-52.
  • Hindie E, Groheux D. Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. J Clin Oncol. 2016 Aug 01;34(22):2673-4.
  • Hindie E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. J Nucl Med. 2016 May;57(5):759-64.
  • Kryza D, Debordeaux F, Azema L, Hassan A, Paurelle O, Schulz J, Savona-Baron C et al. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas. PLoS One. 2016;11(2):e0149387.
  • Laffon E, Burger IA, Lamare F, de Clermont H, Marthan R. SUVpeak Performance in Lung Cancer: Comparison to Average SUV from the 40 Hottest Voxels. J Nucl Med. 2016 Jan;57(1):85-8.
  • Mazere J, Lamare F, Fernandez P, Allard M, Mayo W. 123I-iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies. J Nucl Med. 2016 Jul 28.
  • Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016 Nov;175(4):652-60.
  • Mesguich C, Zanotti-Fregonara P, Hindie E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics. 2016;6(2):287-90.
  • Meyer M, Fernandez P, Zanotti-Fregonara P. 18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus. Clin Nucl Med. 2017 Jan;42(1):42-3.
  • Morgat C, Varshney R, Vimont D, Savona-Baron C, Riès C, Chanseau C, Bertrand S, Mishra AK, Hindié E, Fernandez P, Schulz J, A new class of radiopeptide for PET imaging of neuromedin-B receptors: 68Ga-ranatensin analog. Med Chem Comm. 2016;7:1217-23.
  • Julienne A, Obenaus A, Ichkova A, Savona-Baron C, Pearce WJ et Badaut J. Chronic cerebrovascular dysfunction after traumatic brain injury. J. Neurosci. Res. 2016, 94(7):609-22
  • Morgat C, Velayoudom-Cephise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66.
  • Sagardoy T, Fernandez P, Ghafouri A, Digue L, Haaser T, de Clermont-Galleran H, et al. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up. Head Neck. 2016 Apr;38 Suppl 1:E1271-6.
  • Tonietto M, Rizzo G, Veronese M, Fujita M, Zoghbi SS, Zanotti-Fregonara P, et al. Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches. J Cereb Blood Flow Metab. 2016 Feb;36(2):326-39.
  • Veronese M, Zanotti-Fregonara P, Rizzo G, Bertoldo A, Innis RB, Turkheimer FE. Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot. Neuroimage. 2016 Apr 15;130:1-12.
  • Zanotti-Fregonara P, Chastan M, Edet-Sanson A, Ekmekcioglu O, Erdogan EB, Hapdey S, et al. New Fetal Dose Estimates from 18F-FDG Administered During Pregnancy: Standardization of Dose Calculations and Estimations with Voxel-Based Anthropomorphic Phantoms. J Nucl Med. 2016 Nov;57(11):1760-3.
  • Zanotti-Fregonara P, Xu R, Zoghbi SS, Liow JS, Fujita M, Veronese M, et al. The PET Radioligand 18F-FIMX Images and Quantifies Metabotropic Glutamate Receptor 1 in Proportion to the Regional Density of Its Gene Transcript in Human Brain. J Nucl Med. 2016 Feb;57(2):242-7.


  • Lamare F., Hayad H., Fernandez P., Visvikis D., Local respiratory motion correction (LRMC) for PET/CT imaging: application to lung cancer, Med. Phys., 2015, 42(10): 5903-5912
  • Mazere J., Mayo W., Pariscoat G., Schulz J., Allard M., Fernandez P., Lamare F., Simplified quantification method for in vivo SPECT imaging of the Vesicular Acetylcholine Transporter with 123I-IBVM, J Nucl Med., 2015, 56(6): 862-868
  • Merlin T., Le Pogam A., Fernandez P., Visvikis D., Lamare F., A novel partial volume effects correction technique integrating deconvolution associated with denoising within the PET image reconstruction process, Med. Phys., 2015, 42(2): 804-819
  • Morgat C., Mazere J., Fernandez P., Buj S., Vimont D., Schulz J., Lamare F., A phantom-based method to standardize dose-calibrators for new β+-emitters, Nucl Med Com, 2015, 36(2): 201-206
  • Henriques de Figueiredo B., Zacharatou C., Galland-Girodet S., Benech J., De Clermont-Gallerande H., Lamare F., Hatt M., Digue L., De Mones del Pujol E., Fernandez P., Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers., Strahlenther Onkol., 2015, 191(3): 217-224
  • Debordeaux F, Mishra AK, Hazari P, Ries C, Savona-Baron C, Schulz J, Fernandez P., 99mTc-DTPA-bis-c(RGDfK) a potential alpha(v)beta3 integrin based homobivalent radioligand for imaging neoangiogenesis in malignant glioma and melanoma. RSC Advances, 2015; 5, 60161-60171
  • Laffon E, de Clermont Gallerande H, Lamare F, Marthan R., Liver SUV versus stage in Hodgkin’s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging, 2015; 42(1):164-165.
  • Pinaquy JB, De Clermont H, Pasticier G, Rigou G, Alberti N, Hindié E, Yacoub M, Fernandez P., Comparative effectiveness of [18F]-Fluorocholine PET-CT and pelvic MRI with Diffusion-Weighted Imaging for staging in patients with high risk prostate cancer., Prostate, 2015; 75(3):323-31.
  • Pinaquy JB, Fernandez P, Pasticier G, Parrens M, De Clermont H., Anthracosis Mimicking Mediastinal Lymph Node Metastases With 18F-FCholine in High-Risk Prostate Cancer. Clin Nucl Med., 2015; 40(4):e253-4.
  • Payoux P, Delrieu J., Gallini A., Adel D., Salabert A.S., Hitzel A., Cantet C., Tafani M., De Verbizier D., Darcourt J, Fernandez P, Monteil J., Carrié I., Voisin T., Gilette-Guyonnet S., Pontecorvo M., Vellas B., Andrieu S., Cognitive and functional patterns of non-demented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging., 2015; 42(9):1459-68
  • Aupy J, Bonnet C, Arnould JS, Fernandez P, Marchal C, Zanotti-Fregonara P., Focal inhibitory seizure with prolonged deficit in adult Sturge-Weber syndrome. Epileptic Disord., 2015; 17(3):328-31
  • Gershen LD, Zanotti-Fregonara P, Dustin IH, Liow JS, Hirvonen J, Kreisl WC, Jenko KJ, Inati SK, Fujita M, Morse CL, Brouwer C, Hong JS, Pike VW, Zoghbi SS, Innis RB, Theodore WH., Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein. JAMA Neurol., 2015; 72(8):882-8
  • Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, Veronese M., The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans., 2015; 43(4):586-92
  • Groheux D, Hindié E., Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer. Eur J Nucl Med Mol Imaging., 2015; 42(12):1801-3
  • Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, Espié M, de Roquancourt A, Hindié E, Hatt M, Visvikis D., Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging., 2015; 42(11):1682-91
  • Groheux D, Hindié E., Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered? J Nucl Med., 2015; 56(8):1293
  • Rubello D, Gordien P, Morliere C, Guyot M, Bordenave L, Colletti PM, Hindié E., Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma. Clin Nucl Med., 2015; 40(8):e405-10
  • Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M., Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology., 2015; 277(2):358-71
  • Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E., Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. J Nucl Med., 2015; 56(6):824-31
  • Hindié E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, Henry JF, Taïeb D., The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med., 2015; 56(5):737-44
  • Tlili G, Amraoui S, Mesguich C, Rivière A, Bordachar P, Hindié E, Bordenave L., High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients. J Nucl Cardiol., 2015; 22(4):787-98
  • Hindié E, Groheux D., Pathological complete response in breast cancer. Lancet., 2015; 385(9963):114
  • Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, Hindié E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El Naqa I, Visvikis D., 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med., 2015; 56(1):38-44


  • Lamare F., Lemaitre A., Fernandez P., Rimoldi O.E., Visvikis D., Evaluation of Respiratory and Cardiac Motion Correction Schemes in Dual Gated PET/CT Cardiac Imaging, Med. Phys., 2014, 41(7): 072504
  • Henriques de Figueiredo B., Antoine M., Trouette R., Lagarde P., Petit A., Lamare F., Hatt M., Fernandez P., Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy : a feasibility study. Radiat Oncol 2014; 23(9): 300
  • Laffon E., de Clermont Gallerande H., Lamare F., Marthan R., Estimating the amount of FDG uptake in physiological tissues, Nucl. Med. Biol., 2014, 41(9): 717-720
  • Laffon E., Lamare F., de Clermont Gallerande H., Burger I.A., Marthan R., Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak, Eur. Radiol., 2014, 24(8): 1964-1970
  • Fayad H., Le Pogam A., Lamare F., Fernandez P., Pradier O., Valette G., Visvikis D., Cheze Le Rest C., Influence of partial volume correction in staging of head and neck squamous cell carcinoma using PET/CT, Q J Nucl Med Mol Imaging., 2014, 58(3): 319-28
  • Hazari P.P., Schulz J., Vimont D., Chadha N, Allard M., Szlosek-Pinaud M., Fouquet E. and Mishra A.K., A new SiF-dipropargyl glycerol scaffold as versatile prosthetic group to design dimeric radioligands: Synthesis of [18F]BMPPSiF tracer to image serotonin receptor. ChemMedChem, 2014; 9(2), 337-349.
  • Morgat C, Mishra AK, Varshney R, Allard M, Fernandez P, Hindié E., Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors. J. Nucl. Med, 2014; 55 (10), 1650-1657.
  • de Monès E, Castetbon V, Digue L, Baltazart B, Fernandez P., Diagnosis of Squamous Cell Carcinoma Metastasis With 18F-FDG PET/CT in Stoma After Percutaneous Endoscopic Gastrostomy: A Rare and Poorly Known Iatrogenic Cause of Spread of Head and Neck Cancer. Clin Nucl Med., 2014; 39(6):544-6
  • Toubert ME, Vija L, Vercellino L, Banayan S, Faugeron I, Berenger N, Meas T, Marzola MC, Chondrogiannis S, Hindié E, Rubello D., Additional Diagnostic Value of Hybrid SPECT-CT Systems Imaging in Patients with Differentiated Thyroid Cancer. Am J Clin Oncol., 2014; 37(3):305-13
  • Chlupac J, Filova E, Havlikova J, Matejka R, Riedel T, Houska M, Brynda E, Pamula E, Rémy M, Bareille R, Fernandez P, Daculsi R, Bourget C, Bacakova L, Bordenave L., The Gene Expression of Human Endothelial Cells Is Modulated by Subendothelial Extracellular Matrix Proteins: Short-Term Response to Laminar Shear Stress. Tissue Eng Part A. 2014 Apr 22.
  • Chlupáč J, Filová E, Riedel T, Houska M, Brynda E, Remy-Zolghadri M, Bareille R, Fernandez P, Daculsi R, Bourget C, Bordenave L, Bačáková L., Attachment of human endothelial cells to polyester vascular grafts: pre-coating with adhesive protein assemblies and resistance to short-term shear stress. Physiol Res., 2014; 63(2):167-77
  • Taïeb D, Hindié E., Imaging secondary hyperparathyroidism. AJR Am J Roentgenol., 2014; (5):W552
  • Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL., 18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Eur J Radiol., 2014; 83(10):1925-33
  • Groheux, D., Ferre, R., Rubello, D., Vercellino, L., Hindie, E., Breast Cancer Patient with an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. Clin Nucl Med., 2014; 39(2):176-9
  • Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M., Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer., 2014; 50(11):1864-71
  • Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL., (18)F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Eur J Radiol., 2014; 83(10):1925-33
  • Zanotti-Fregonara P, Zhang Y, Jenko KJ, Gladding RL, Zoghbi SS, Fujita M, Sbardella G, Castellano S, Taliani S, Martini C, Innis RB, Da Settimo F, Pike VW., Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971. ACS Chem Neurosci., 2014; 5(10):963-71.


  • Mazere J., Meissner W.G., Sibon I., Lamare F., Tison F., Allard M., Mayo W., [123I]-IBVM SPECT imaging of cholinergic systems in Multiple System Atrophy: a specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6), NeuroImage Clin., 2013, 3: 212-217
  • Henriques de Figueiredo B., Merlin T., de Clermont Gallerande H., Hatt M., Fernandez P., Lamare F., Potential of 18F-Fluoromisonidazole PET for Radiotherapy Planning in Head and Neck Squamous Cell Carcinomas, Strahlenther Onkol., 2013, 189(12): 1015-1019
  • Varshney, R., Hazari P., Fernandez P., Schulz J., Allard M, Mishra AK., 68Ga-labeled bombesin analogs for receptor-mediated imaging. Recent results in Cancer Research, 2013; 1, volume 194, 221-256.
  • Morgat C., Hindié E., Mishra A.K., Allard M., Fernandez P., Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways., Cancer Biother Radiopharm. 2013;28(2):85-97
  • Laffon E., de Clermont Gallerande H., Lamare F., Marthan R., Variability of total lesion glycolysis by 18F-FDG-positive tissue thresholding in lung cancer, J Nucl Med Tech, 2013, 41(3): 186-191
  • Lamare F., Mazere J., Attila M., Mayo W., De Clermont-Gallerande H., Meissner W., Fernandez P., Allard M., Improvement of in vivo quantification of [123I]-IBVM in SPECT/CT imaging using anatomical image to brain atlas non-rigid registration, Mol Imaging., 2013, 12(5): 288-299
  • Fayad H., Lamare F., Cheze Le Rest C., Bettinardi V., Visvikis D., Generation of 4-Dimensional CT Images Based on 4-Dimensional PET-Derived Motion Fields, J Nucl Med., 2013, 54(4): 631-638
  • Pogam A., Lamare F., Hatt M., Fernandez P., Cheze Le Rest C., Visvikis D., MRI data driven partial volume effects correction in PET imaging using 3D local multi-resolution analysis, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2013, 702: 39-41
  • Thureau S., Chaumet-Riffaud P., Modzelewski R., Fernandez P., Tessonnier L., Vervueren L., Cachin F., Berriolo-Riedinger A., Olivier P., Kolesnikov-Gautier H., Blagosklonov O., Bridji B., Devillers A., Collombier L., Courbon F., Gremillet E., Houzard C., Caignon J.M., Roux J., Aide N., Brenot-Rossi I., Doyeux K., Dubray B., Vera P., Interobserver Agreement of Qualitative Analysis and Tumor Delineation of FMISO and FLT PET-images in Lung Cancer. J. Nucl. Med., 2013; 54(9):1543-50.
  • Grassetto G, Groheux D, Marzola MC, Hindié E, Al-Nahhas A, Rubello D., FDG PET/CT in ovarian cancer: what about treatment response and prognosis? Clin Nucl Med., 2013; 37(1):54-6
  • Fernandez P, De Clermont-Gallerande H, Dauchy F, Massaloux K, Dupon M., Molecular imaging of infection of hip and knee joint prosthesis. Med. Nuc., 2013; 37:353-361
  • Bacigalupo, L., Groheux, D., Hindie, E., Whole-body 18FDG-PET/CT or whole-body gadolinium-enhanced MRI for distant staging? Ann Oncol.,2013; 24, 9-13
  • Cuenca, X., Hennequin, C., Hindie, E., Rivera, S., Vercellino, L., Baruch-Hennequin, V., Gornet, J.M., Cattan, P., Chirica, M., Quero, L., Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging., 2013; 40, 477-85
  • Hatt, M., Groheux, D., Martineau, A., Espie, M., Hindie, E., Giacchetti, S., de Roquancourt, A., Visvikis, D., Cheze-Le Rest, C., Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med., 2013; 54, 341-9
  • Groheux, D., Hatt, M., Hindie, E., Giacchetti, S., de Cremoux, P., Lehmann-Che, J., Martineau, A., Marty, M., Cuvier, C., Cheze-Le Rest, C., de Roquancourt, A., Visvikis, D., Espie, M., Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with 18F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer., 2013; 119, 1960-8
  • Groheux, D., Delord, M., Rubello, D., Colletti, P.M., Nguyen, M.L., Hindie, E., Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med., 2013; 38, 422-5
  • Groheux, D., Espie, M., Giacchetti, S., Hindie, E., Performance of FDG PET/CT in the clinical management of breast cancer. Radiology., 2013; 266, 388-405
  • Groheux, D., Giacchetti, S., Delord, M., Hindie, E., Vercellino, L., Cuvier, C., Toubert, M.E., Merlet, P., Hennequin, C., Espie, M., 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med., 2013; 54, 5-11
  • Groheux, D., Giacchetti, S., Hatt, M., Marty, M., Vercellino, L., de Roquancourt, A., Cuvier, C., Coussy, F., Espie, M., Hindie, E., HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer., 2013; 109, 1157-64
  • Groheux, D., Teyton, P., Vercellino, L., Ferretti, A., Rubello, D., Hindie, E., Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. Biomed Pharmacother., 2013; 67, 533-8
  • Taieb, D., Urena-Torres, P., Zanotti-Fregonara, P., Rubello, D., Ferretti, A., Henter, I., Henry, J.F., Schiavi, F., Opocher, G., Blickman, J.G., Colletti, P.M., Hindie, E., Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. Clin Nucl Med., 2013; 38, 630-5


  • Mazere J., Meissner W.G., Mayo W., Sibon I., Lamare F., Guilloteau D. , Tison F., Allard M., Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol, Radiology, 2012, 265(2): 537-543
  • Amigues, E., Schulz J., Slozek-Pinaud M., Fernandez P., Silvente-Poirot S., Brillouet S., Courbon F., Fouquet E., [18F]Si-RiboRGD: From design and synthesis to the imaging of αvβ3-integrins in melanoma tumors. ChemPlusChem, 2012; 77, 345-349.
  • Taieb D, Hindie E, Grassetto G, Colletti PM, Rubello D., Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med., 2012; 37(6):568-74.
  • Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E., Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med., 2012;53(2):264-74.
  • Groheux D, Hindié E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, Vercellino L, Berenger N, Marty M, Espié M., Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med., 2012; 53(2):249-54.
  • Hindié E, Groheux D, Hennequin C, Zanotti-Fregonara P, Vercellino L, Berenger N, Toubert ME, Maylin C, Vilcoq JR, Espié M., Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy. Int J Radiat Oncol Biol Phys., 2012; 15; 83(4):1081-8.